– SWITZERLAND, Baar – CorFlow Therapeutics AG announced the appointment of Chris O’Connell as Chairman of the Board of Directors, replacing Rick Geoffrion, who remains on the Board.
Paul Mead, CEO said “Chris brings exceptional strategic and operational acumen to CorFlow at a pivotal growth phase, where the company can benefit tremendously from his experience. Chris knows exactly how high the bar is set for excellence across all functions in MedTech, both from his corporate and board experiences, and from having been on the buy side of many M&A transactions. On behalf of our board, shareholders, and employees, we’re thrilled to have him on board.”
About Chris O’Connell
Chris O’Connell is a highly regarded senior executive, board member, and advisor across the medical devices, life sciences, and global healthcare industries. He built his career over 21 years at Medtronic (MDT), serving in multiple business areas and functions during an era of rapid expansion. This included senior leadership roles in the Cardiovascular and Diabetes business units, before becoming EVP and President of the Restorative Therapies Group.
Chris O’Connell was a member of the Medtronic Executive Committee for nine years. Chris later became CEO and President of the Waters Corporation, which he led to robust business and share price growth for over five years. He serves as an Independent Director of innovative growth companies in medical devices, life sciences, and diagnostics, as well as several non-profit organizations.
Chris O’Connell joins CorFlow as the company embarks on achieving ambitious Series B objectives, which include two parallel clinical trials, an FDA IDE trial to obtain marketing authorization in the United States, and a landmark randomized therapy trial in Europe.
Chris O’Connell said, “I am honored to join the CorFlow team, and highly motivated by the opportunity to help address a major unmet medical need for patients suffering from microvascular obstruction. CorFlow is poised for breakthrough success with such a transformative technology set, talented CEO and team, and experienced investor group. We have all the ingredients to achieve something special.”
About CorFlow Therapeutics
Headquartered in Baar, Switzerland. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich, and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications in and beyond the heart.
For more: https://corflow.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.